Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489956 · ClinicalTrials.gov registry record · Early Phase 1
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
A Early Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT01489956 is a Early Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 19 participants.
The verdict
NCT01489956, a Early Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to test the oral tolerance of Keyhole Limpet Hemocyanin (KLH) and to determine if Immucothel by itself is strong enough to trigger the immune response. If not, Immucothel will be tested in combination with an adjuvant to determine if an adequate immune response can be seen.
Interventions
- BIOLOGICAL Immucothel Alone (Part A)
- BIOLOGICAL Immucothel+Montanide (Part A)
- BIOLOGICAL Immucothel Alone or Immucothel+Montanide (Part B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489956
The ClinicalTrials.gov registry entry for NCT01489956 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Immucothel Alone (Part A) is the first listed.
NCT01489956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489956 about?
NCT01489956 is a clinical study titled "A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)". The purpose of this study is to test the oral tolerance of Keyhole Limpet Hemocyanin (KLH) and to determine if Immucothel by itself is strong enough to trigger the immune response. If not, Immucothel will be tested in combination with an adjuvant to determine if an adequate immune response can be se...
What is the current status of trial NCT01489956?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2011-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01489956?
The interventions under investigation include: Immucothel Alone (Part A) (BIOLOGICAL), Immucothel+Montanide (Part A) (BIOLOGICAL), Immucothel Alone or Immucothel+Montanide (Part B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01489956?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.